Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liver Neoplasms × ADI PEG20 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2 Resectable Hepatocellular Carcinoma 1 Mesothelioma, Malignant 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1

Interventions

Bevacizumab 21 Sorafenib 17 Doxorubicin 11 Oxaliplatin 10 Fluorouracil 10 durvalumab 9 Gemcitabine 9 Cisplatin 9 Nivolumab 7 Capecitabine 7 pembrolizumab 6 tremelimumab 5 atezolizumab 5 Sunitinib 5 Neoadjuvant Therapy 5 Leucovorin 5 aldesleukin 4 Radiosurgery 4 Radiofrequency Ablation 4 Drug Therapy 4 lenvatinib 3 camrelizumab 3 apatinib 3 Radiotherapy 3 Mitomycin 3 Liver Transplantation 3 Idarubicin 3 Everolimus 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02006030 2018-09-04

TACE

Polaris Group

Phase 2 Completed

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡